Dr Martin Mackay

Martin is a co-founder of Rallybio.  He has worked in pharmaceutical and biotech research and development for over 30 years in leadership roles with some of the most prominent pharmaceutical companies in the world.

Martin was previously head of research and development at Alexion Pharmaceuticals where he led a group of over 600 scientists and oversaw the growth of the company from a one product (Soliris) with two indications, (Paroxysmal Nocturnal Hemoglobinuria – PNH and atypical Hemolytic Uremic Syndrome – aHUS) enterprise to a company with three products (Soliris, Strensiq and Kanuma) and five indications (PNH, aHUS, refractory Myasthenia Gravis – rMG), Hypophosphatasia – HPP, and Lysosomal Acid Lipase Deficiency – LAL-D). Moreover, he led the growth of Alexion’s research and development portfolio to over 30 research programs, over 30 biotech and academic alliances, and 10 clinical development programs with key product readouts in 2018 and 2019.

Prior to Alexion, Martin was head of research and development at AstraZeneca where he led the global organisation responsible for discovering and developing new medicines across a range of disease areas including respiratory and inflammation, oncology, infectious diseases, cardiovascular, gastrointestinal, and neuroscience. He oversaw over 10,000 colleagues in discovery research, drug development, clinical development and operations, regulatory affairs, pharmaceutical development, drug metabolism and pharmacokinetics, and business functional support lines, and managed an annual research and development budget of over $5 billion USD. Notable products launched included Brilinta, Farxiga and Caprelsa.

Martin also spent 15 years at Pfizer in positions of increasing responsibility and led the research and development and pharmaceutics organizations. His oversight included an international network of scientists and other pharmaceutical research and development professionals in research, development operations, pharmaceutical sciences, drug safety, and their respective functional lines. Under his leadership, his team advanced a portfolio of investigational medicines in several research units including, allergy and respiratory, antibacterials, antivirals, cardiovascular and metabolic diseases, genitourinary, neuroscience, oncology, and pain. Martin also worked closely with business development on major acquisitions, licensing and development and strategic alliances. Prior to his departure, he helped the company prepare for the launch of Xeljanz, Xalkori, and Eliquis following actively being involved in the notable launches of Selzentry, Chantix, Sutent and Lyrica.

Martin obtained a First Class Honours degree in Microbiology from Heriot-Watt University and his PhD in Molecular Genetics from the University of Edinburgh. His postdoctoral studies on developing a vaccine for Malaria was conducted at the University of Edinburgh and funded by the Medical Research Council and Hoffmann-La Roche. Martin is well-known in the pharmaceutical industry and he continues to be sought out as a subject matter expert and frequently lectures and consults with others. He is currently a member of the Board of Directors of Charles River Laboratories.

Martin summarizes the 3 loves in his life as being family, work, and soccer, but not necessarily in that order.